CD8A and type 1 diabetes mellitus: Although the precise mechanisms of nivolumab-induced T1DM are not fully understood, activated CD8+ T cells have been speculated to evoke autoimmunity against pancreatic beta cells and to destroy them, resulting in insulin exhaustion [12].